2834 completed, 505 unknown, 335 recruiting, 229 terminated. 1209 Not applicable, 735 Phase 3, 623 Phase 2, 545 Phase 1, 416 Phase 4.
Follow Lipid Metabolism Disorders: new trials by email Literature Review of Lipid Metabolism Disorders trials Research Report on Lipid Metabolism Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patient-engaged Development and Testing of Educational Content on Side Effects of Statins Educational content on statin side effects - Dyslipidemia | Not applicable | Suspended | Weill Medical College of Cornell University | 30 | 2028-09-01 | 2026-09-23 |
| Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD Lentiviral TYF-ARSA correction of patient's autologous HSCs - Metachromatic Leukodystrophy (MLD) | Not applicable | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-01 | 2026-09-01 |
| Direct Lentiviral Injection Gene Therapy for MLD Intrathecal and intravenous LV gene therapy - Metachromatic Leukodystrophy (MLD) | Not applicable | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-05-31 | 2026-09-01 |
| Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose Pecan, Control - Nutrition, Healthy, Dyslipidemia | Not applicable | Not yet recruiting | University of Georgia | 90 | 2027-03-01 | 2026-08-11 |
| Coronary Artery Calcium (CAC) Testing in Primary Care Our Practice Advisory (OPA) - ASCVD, ASCVD Management | Not applicable | Not yet recruiting | Weill Medical College of Cornell University | 20 | 2027-02-01 | 2026-10-15 |
| PCSK9 Inhibitors in Hyperlipidemia and Atherosclerosis Hyperlipidemia, Atherosclerotic Cardiovascular Disease (ASCVD) | Not yet recruiting | Fundación Santa Fe de Bogota | 100 | 2027-02-01 | 2026-10-02 | |
| A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia | Phase 4 | Not yet recruiting | Amgen | 308 | 2027-01-31 | 2026-09-21 |
| A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion Gaucher Disease | Not yet recruiting | Takeda | 60 | 2027-01-31 | 2026-10-01 | |
| Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis Clinical Trial Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase - GM1 Gangliosidoses, GM1 Gangliosidosis, Type I | Phase 1 | Not yet recruiting | Tippi Mackenzie | 5 | 2027-01-01 | 2026-08-31 |
| RCT for the Chinese Medicine in Treating Hypercholesterolemia Dachaihu Decoction combined Erzhiwan with variation, Placebo granules - Hypercholesterolemia | Phase 2 | Not yet recruiting | Chinese University of Hong Kong | 70 | 2027-01-01 | 2026-07-30 |
| 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma GD2, PSMA and CD276 CAR-T cells - Neuroblastoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2026-12-31 | 2026-09-01 |
| Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders AZ-3102 - Niemann-Pick Disease Type C, GM2 Gangliosidosis | Phase 2 / Phase 3 | Not yet recruiting | Azafaros B.V. | 218 | 2026-12-10 | 2026-10-21 |
| Germany on Target Registry No study-assigned intervention - Myocardial Infarction (MI), Dyslipidemias | Not yet recruiting | Deutsche Gesellschaft für Lipidologie e. V. (DGFL) - Lipid-Liga | 10000 | 2026-12-01 | 2026-09-28 | |
| Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol) PLX-200 - Lysosomal Storage Disorders, Sandhoff Disease | Phase 2 | Not yet recruiting | Polaryx Therapeutics, Inc. | 24 | 2026-12-01 | 2026-07-31 |
| Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3 PLX-200, Placebo - Juvenile Neuronal Ceroid Lipofuscinosis | Phase 3 | Withdrawn | Polaryx Therapeutics, Inc. | 2026-11-01 | 2026-08-19 | |
| Therapeutic Implications of CMR Low Native T1 in Non-treated Non-hypertrophic Females With Fabry Disease (FD) Decision tree for initiating treatment - Fabry Disease | Not applicable | Not yet recruiting | University Hospital, Bordeaux | 60 | 2026-11-01 | 2026-10-14 |
| A Phase 1 Study of VELA-101 in Adult Participants VELA-101, Placebo - Healthy Participants, Hyperlipidemia | Phase 1 | Not yet recruiting | Ursa Medicines | 60 | 2026-11-01 | 2026-10-15 |
| Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia EDP167 100mg, EDP167 200mg, EDP167 300mg - Mixed Dyslipidemia | Phase 2 | Not yet recruiting | Eddingpharm (Zhuhai) Co., Ltd. | 144 | 2026-11-01 | 2026-09-02 |
| Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks No intervention; observational assessment only - Obesity & Overweight, Diabetes Mellitus, Type 2 | Not yet recruiting | Shanxi Bethune Hospital | 25974 | 2026-11-01 | 2026-10-21 | |
| Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk Bupropion 150 mg, Lyophilized powder from edible mushrooms, Lifestyle Management - Cardiometabolic Syndrome, Obesity and Cardiovascular Risk | Phase 3 | Not yet recruiting | Uppsala University | 250 | 2026-10-30 | 2026-09-08 |
Showing 20 of 4344. Sign in to see all of them.
Dyslipidemias (1193) · Hypercholesterolemia (1130) · Hyperlipidemias (843) · Hypertension (622) · Diabetes Mellitus (440) · Obesity (411) · Cardiovascular Diseases (373) · Hypertriglyceridemia (315) · Diabetes Mellitus, Type 2 (273) · Fabry Disease (243) · Hyperlipoproteinemia Type II (224) · Metabolic Syndrome (218) · Atherosclerosis (181) · Gaucher Disease (175)
Nutritional and Metabolic Diseases (4337) · Metabolic Diseases (4260) · Dyslipidemias (2201) · Hyperlipidemias (1487) · Vascular Diseases (1219) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1186) · Genetic Diseases, Inborn (1143) · Lipid Metabolism, Inborn Errors (1119) · Metabolism, Inborn Errors (1090) · Cardiovascular Diseases (1072) · Pathological Conditions, Signs and Symptoms (871) · Glucose Metabolism Disorders (862) · Nervous System Diseases (766) · Endocrine System Diseases (728)
Atorvastatin (270) · Ezetimibe (210) · Rosuvastatin Calcium (193) · Simvastatin (134) · Fenofibrate (81) · evolocumab (65) · alirocumab (60) · Metformin (52) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (51) · Exercise (49) · Niacin (48) · Pravastatin (44) · pitavastatin (41) · Omacor (36) · Diet (34)
AstraZeneca (130) · Organon and Co (100) · Takeda (72) · Sanofi (66) · Merck Sharp & Dohme LLC (59) · Pfizer (53) · Chong Kun Dang Pharmaceutical (50) · National Heart, Lung, and Blood Institute (NHLBI) (49) · Novartis Pharmaceuticals (46) · Amgen (44) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (41) · Genzyme, a Sanofi Company (37) · Shire (34) · Amicus Therapeutics (29) · Regeneron Pharmaceuticals (27)
United States (1544) · Canada (426) · South Korea (297) · China (292) · United Kingdom (285) · France (272) · Germany (267) · Italy (245) · Spain (227) · Netherlands (213) · Australia (166) · Brazil (146) · Poland (137) · Denmark (136) · Czechia (127)
Forbes D Porter, M.D. (11) · David JA Jenkins, MD, PhD, DSc (10)
PMID 30183102, PMID 33078867, PMID 37994400, PMID 21518985, PMID 27777279, PMID 34298554, PMID 38018702, PMID 27657681, PMID 28181260, PMID 40587053, PMID 19793357, PMID 28304227, PMID 28324110, PMID 28964736, PMID 29685591, PMID 33990512, PMID 35277540, PMID 18783301, PMID 25614280, PMID 27578134, PMID 31194872, PMID 32609313, PMID 34677608, PMID 35916348, PMID 37565307, PMID 38063346, PMID 19744248, PMID 20136164, PMID 20573750, PMID 21586746, PMID 22301925, PMID 23661689, PMID 24239923, PMID 26872608, PMID 27206567, PMID 27659698, PMID 27839979, PMID 27888609, PMID 28391886, PMID 29037448, PMID 33332761, PMID 34617591, PMID 36279795, PMID 36520008, PMID 37624739, PMID 37658997, PMID 38504437, PMID 38757725, PMID 39847314, PMID 40525490
2015 (23), 2005 (22), 2023 (18), 2019 (12), U54NS065768 (12), 2017 (11), 2025 (11), 2016 (10), 2014 (9), 2018 (9), 2008 (8), 2009 (5), OT2HL158287 (5), R01HL168858 (3), 2004 (2)